Squarepoint Ops LLC trimmed its stake in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) by 71.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 26,179 shares of the company's stock after selling 64,180 shares during the period. Squarepoint Ops LLC's holdings in Evolus were worth $289,000 as of its most recent SEC filing.
Other hedge funds have also modified their holdings of the company. Tang Capital Management LLC lifted its stake in Evolus by 3.1% in the 4th quarter. Tang Capital Management LLC now owns 4,997,399 shares of the company's stock worth $55,171,000 after acquiring an additional 150,000 shares in the last quarter. Nantahala Capital Management LLC lifted its stake in Evolus by 10.8% in the 4th quarter. Nantahala Capital Management LLC now owns 3,130,149 shares of the company's stock worth $34,557,000 after acquiring an additional 305,300 shares in the last quarter. Caligan Partners LP lifted its stake in Evolus by 22.7% in the 4th quarter. Caligan Partners LP now owns 2,692,388 shares of the company's stock worth $29,724,000 after acquiring an additional 498,900 shares in the last quarter. Millennium Management LLC lifted its stake in Evolus by 29.1% in the 4th quarter. Millennium Management LLC now owns 1,368,423 shares of the company's stock worth $15,107,000 after acquiring an additional 308,753 shares in the last quarter. Finally, Boothbay Fund Management LLC lifted its stake in Evolus by 30.9% in the 4th quarter. Boothbay Fund Management LLC now owns 1,287,767 shares of the company's stock worth $14,217,000 after acquiring an additional 304,065 shares in the last quarter. 90.69% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
EOLS has been the topic of several research reports. Needham & Company LLC reaffirmed a "buy" rating and issued a $22.00 target price on shares of Evolus in a research report on Thursday, May 8th. Barclays upped their target price on Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. BTIG Research assumed coverage on Evolus in a report on Thursday, April 17th. They set a "buy" rating and a $21.00 price objective on the stock. Finally, HC Wainwright reissued a "buy" rating and set a $27.00 price objective on shares of Evolus in a report on Thursday, April 10th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Evolus presently has a consensus rating of "Buy" and a consensus price target of $23.75.
View Our Latest Report on EOLS
Insider Activity at Evolus
In other Evolus news, insider Rui Avelar sold 3,385 shares of the firm's stock in a transaction on Monday, May 12th. The stock was sold at an average price of $9.87, for a total transaction of $33,409.95. Following the transaction, the insider now owns 359,082 shares in the company, valued at $3,544,139.34. This trade represents a 0.93% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Karah Herdman Parschauer sold 12,888 shares of the firm's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $12.99, for a total value of $167,415.12. Following the transaction, the director now owns 32,183 shares in the company, valued at approximately $418,057.17. This trade represents a 28.59% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 86,241 shares of company stock valued at $1,048,666. Insiders own 5.90% of the company's stock.
Evolus Trading Up 3.1%
EOLS stock opened at $10.04 on Friday. The company has a market cap of $647.34 million, a P/E ratio of -11.03 and a beta of 1.11. Evolus, Inc. has a twelve month low of $8.67 and a twelve month high of $17.82. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58. The business has a fifty day moving average of $10.39 and a 200-day moving average of $11.90.
About Evolus
(
Free Report)
Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Read More
Want to see what other hedge funds are holding EOLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Evolus, Inc. (NASDAQ:EOLS - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Evolus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolus wasn't on the list.
While Evolus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
